Vincerx Pharma Files 8-K: Material Agreement, Other Events
Ticker: VINC · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $30,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
Related Tickers: VINC
TL;DR
Vincerx Pharma (VINC) filed an 8-K on Jan 21, 2025, reporting a material definitive agreement. Details to follow.
AI Summary
On January 21, 2025, Vincerx Pharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company, formerly known as Vincera Pharma, Inc. and LifeSci Acquisition Corp., is headquartered in Palo Alto, California.
Why It Matters
This 8-K filing signals a significant development for Vincerx Pharma, Inc., potentially involving a new material agreement that could impact its business operations and future prospects.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant new risks or opportunities, the nature of which is not yet fully disclosed in this initial filing.
Key Numbers
- 001-39244 — SEC File Number (Identifies the company's filing with the SEC)
- 83-3197402 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Vincerx Pharma, Inc. (company) — Registrant
- Vincera Pharma, Inc. (company) — Former company name
- LifeSci Acquisition Corp. (company) — Former company name
- January 21, 2025 (date) — Date of report
FAQ
What is the nature of the material definitive agreement filed by Vincerx Pharma, Inc. on January 21, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information of the 8-K.
What were Vincerx Pharma, Inc.'s former company names?
Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. (name change effective December 23, 2020) and LifeSci Acquisition Corp. (name change effective December 6, 2019).
Where is Vincerx Pharma, Inc. headquartered?
Vincerx Pharma, Inc. is headquartered at 1825 S. Grant Street, San Mateo, California, 94402.
What is the SIC code for Vincerx Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Vincerx Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 8-K report?
The 8-K report was filed on January 21, 2025.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 9.1 · Accepted 2025-01-21 16:31:34
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
- $30,000,000 — ng an aggregate offering price of up to $30,000,000 (the "Shares"). Pursuant to the Agreeme
Filing Documents
- d927067d8k.htm (8-K) — 28KB
- d927067dex51.htm (EX-5.1) — 5KB
- d927067dex101.htm (EX-10.1) — 235KB
- d927067dex991.htm (EX-99.1) — 11KB
- 0001193125-25-009577.txt ( ) — 473KB
- vinc-20250121.xsd (EX-101.SCH) — 3KB
- vinc-20250121_lab.xml (EX-101.LAB) — 18KB
- vinc-20250121_pre.xml (EX-101.PRE) — 11KB
- d927067d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Sales Agreement dated January 21, 2025 between Vincerx Pharma, Inc. and H.C. Wainwright & Co., LLC. 5.1 Opinion of Pillsbury Winthrop Shaw Pittman LLP. 23.1 Consent of Pillsbury Winthrop Shaw Pittman LLP (included in Exhibit 5.1). 99.1 Disclosures. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 21, 2025 VINCERX PHARMA, INC. By: /s/ Raquel E. Izumi Name: Raquel E. Izumi Title: Acting Chief Executive Officer